Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICM-403
- Development stage
- Preclinical
- Lead developer
- Creative Artists Agency
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
ICM-403 is an adeno-associated virus (AAV)-based gene therapy developed by ICM Co., Ltd. for the treatment of congenital hearing loss. It specifically targets mutations in the *SLC26A4* gene, which encodes the protein Pendrin. Pendrin mutations are a leading cause of hereditary sensorineural hearing loss, particularly in East Asian populations, and are associated with Pendred syndrome and enlarged vestibular aqueduct (EVA). The therapy aims to deliver a functional copy of the *SLC26A4* gene to the inner ear to restore Pendrin function and improve hearing outcomes. It is currently in preclinical development and has completed small-scale production for research purposes.
- Other names
- ICM-403 AAV gene therapyICM403 AAV gene therapyICM 403 AAV gene therapy
02
Targets
Neuraminidase
Beyond the preview
Go deeper on ICM-403.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICM-403.